Clinical Trial Update: Intrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intrathecal baclofen therapy for paroxysmal dysautonomia in severe brain-injured patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Anoxia
• Coma
• Dysautonomia
• Hypertonia
• Traumatic Brain Injury

Drugs mentioned

• BACLOFEN (Baclofen)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Traumatic Brain Injury, Cerebral Anoxia | Phase 2 | Status: TERMINATED